The prognostic impact of the loss of RBM3 expression is markedly pronounced in estrogen receptor (ER)-positive breast cancer compared with ER-negative tumors [40], whereas RBM3 overexpression is a good prognostic marker in prostate cancer, which is governed by androgen receptor (AR) signaling [35]. This evidence concerns the gene AR and prostate carcinoma.